London Daily

Focus on the big picture.
Monday, Oct 20, 2025

NHS drug pledge broken for asthma sufferers and smokers, report reveals

NHS drug pledge broken for asthma sufferers and smokers, report reveals

Exclusive: Charities critical of failure to meet health plan for England, despite 2019 agreement
A promise to ensure that people with severe asthma and smokers who want to quit can get the drugs they need has been broken by ministers and the NHS, a health service report reveals.

Health charities criticised the persistent lack of access to vital medications for patients in England as very worrying and warned that it could damage the health of those affected.

In 2019 the Department of Health and Social Care (DHSC), NHS England, Association of the British Pharmaceutical Industry (ABPI) and makers of branded medicines signed an agreement, called the voluntary scheme, to increase the number of patients able to obtain cost-effective medicines on the NHS.

It covered five key areas of disease in which receipt of drugs would result in “high health gain”. These were cystic fibrosis, severe asthma, stopping smoking by using the drug varenicline, hepatitis C and atrial fibrillation and thromboembolism, a heart problem. The plan was to ensure that England became one of the best countries in Europe for access to relevant medications.

However, a report which NHS England commissioned – but has not published – shows that while the target has been met for cystic fibrosis and hepatitis C, it has been missed for severe asthma and smokers seeking to quit using varenicline. It compares England’s progress against that in 10 other European countries, including France, Spain and Italy.

“It’s deeply concerning that England languishes near the bottom of the league table for uptake of biologic treatments for severe asthma, the deadliest form of the condition,” said Alison Cook, the director of external affairs at Asthma UK and the British Lung Foundation.

Four in five of the 200,000 Britons with the condition are missing out on drugs because they are not being referred to hospital specialists, she added. However, she welcomed the success in more patients with cystic fibrosis getting medication as “brilliant”.

Varenicline, which is better known as Champix, and is made by Pfizer, was withdrawn from use in the UK in June over concerns about the impurity of its key ingredient.

Hazel Cheeseman, the deputy chief executive of the smoking health charity Ash, said: “The fact that despite setting this as a priority, the NHS has failed to deliver is concerning, and indicates the entrenched problems of getting smoking cessation taken more seriously in the NHS at a time when they are starting to roll out a big programme to increase support for smokers in inpatient, maternity and mental health settings through the [NHS] long-term plan.”

The report, drawn up by the health data analytics firm LOGEX, did not investigate the reasons for the disparities in access between the 11 countries. However, it speculated that “possible factors … may include introduction times, reimbursement policies or national guidelines”, suggesting that NHS England and the National Institute for Health and Care Excellence’s policies may be factors.

Dr Andrew Hill, an expert in the drugs industry at Liverpool University, said that high-profile campaigns to secure better access to drugs for cystic fibrosis and hepatitis C may explain why the pledge has been met for those conditions but not for severe asthma and smokers seeking to quit.

“There was a four-year stand-off between [drugmaker] Vertex and NHS England from 2015 to 2019” when prices for its cystic fibrosis drug Orkambi could not be agreed,” said Hill, a senior visiting fellow in the university’s department of pharmacology and therapeutics.

“During these four years, hundreds of children with cystic fibrosis died without access to the drugs they needed. Families had to form a buyers club to import generic versions of the drug. It was only after intense campaigning that [then] health secretary Matt Hancock finally agreed a confidential deal with Vertex to supply the drugs.”

Similarly, Hill added, the drug company Gilead’s decision to charge $84,000 (£63,000) for its hepatitis C drug again led to patients in the UK setting up buyers clubs to import cheap versions of the medicine. Access improved when NHS England used competitive tenders from hepatitis C drugs, which led to several firms making treatments for the disease lowering prices for their products.

“Patient groups were fighting for access to medicines for heptatitis C and cystic fibrosis for years before this survey started. We have not seen these intense campaigns for the other drugs in the survey. This could explain the differences seen,” added Hill.

Richard Torbett, the ABPI’s chief executive, urged ministers to increase UK spending on drugs, which he said was the lowest among the G7 group of rich nations.

“There has been a concerted effort in the NHS to improve access to new medicines – through initiatives like the accelerated access collaborative. But this report shows there is room for improvement, including for asthma patients,” he said.

“The UK has the lowest proportional investment in medicines of the G7, and other countries are ahead of the game in the way they diagnose and treat conditions. We need to look to their success if we are to improve patient outcomes in the UK,” he added.

A DHSC spokesperson said: “One of our top priorities is improving outcomes for patients with respiratory disease, and the NHS is rolling out tobacco dependence treatment services, on top of local authority services to help more smokers get support.”
Newsletter

Related Articles

0:00
0:00
Close
This Is How the 'Heist of the Century' Was Carried Out at the Louvre in Seven Minutes: France Humiliated as Crown with 2,000 Diamonds Vanishes
China Warns UK of ‘Consequences’ After Delay to London Embassy Approval
France’s Wealthy Shift Billions to Luxembourg and Switzerland Amid Tax and Political Turmoil
"Sniper Position": Observation Post Targeting 'Air Force One' Found Before Trump’s Arrival in Florida
Shouting Match at the White House: 'Trump Cursed, Threw Maps, and Told Zelensky – "Putin Will Destroy You"'
Windows’ Own ‘Siri’ Has Arrived: You Can Now Talk to Your Computer
Thailand and Singapore Investigate Cambodian-Based Prince Group as U.S. and U.K. Sanctions Unfold
‘No Kings’ Protests Inflate Numbers — But History Shows Nations Collapse Without Strong Executive Power
Chinese Tech Giants Halt Stablecoin Launches After Beijing’s Regulatory Intervention
Manhattan Jury Holds BNP Paribas Liable for Enabling Sudanese Government Abuses
Trump Orders Immediate Release of Former Congressman George Santos After Commuting Prison Sentence
S&P Downgrades France’s Credit Rating, Citing Soaring Debt and Political Instability
Ofcom Rules BBC’s Gaza Documentary ‘Materially Misleading’ Over Narrator’s Hamas Ties
Diane Keaton’s Cause of Death Revealed as Pneumonia, Family Confirms
Former Lostprophets Frontman Ian Watkins Stabbed to Death in British Prison
"The Tsunami Is Coming, and It’s Massive": The World’s Richest Man Unveils a New AI Vision
Outsider, Heroine, Trailblazer: Diane Keaton Was Always a Little Strange — and Forever One of a Kind
Dramatic Development in the Death of 'Mango' Founder: Billionaire's Son Suspected of Murder
Two Years of Darkness: The Harrowing Testimonies of Israeli Hostages Emerging From Gaza Captivity
EU Moves to Use Frozen Russian Assets to Buy U.S. Weapons for Ukraine
Europe Emerges as the Biggest Casualty in U.S.-China Rare Earth Rivalry
HSBC Confronts Strategic Crossroads as NAB Seeks Only Retail Arm in Australia Exit
U.S. Chamber Sues Trump Over $100,000 H-1B Visa Fee
Shenzhen Expo Spotlights China’s Quantum Step in Semiconductor Self-Reliance
China Accelerates to the Forefront in Global Nuclear Fusion Race
Yachts, Private Jets, and a Picasso Painting: Exposed as 'One of the Largest Frauds in History'
Australia’s Wedgetail Spies Aid NATO Response as Russian MiGs Breach Estonian Airspace
McGowan Urges Chalmers to Cut Spending Over Tax Hike to Close $20 Billion Budget Gap
Victoria Orders Review of Transgender Prison Placement Amid Safety Concerns for Female Inmates
U.S. Treasury Mobilises New $20 Billion Debt Facility to Stabilise Argentina
French Business Leaders Decry Budget as Macron’s Pro-Enterprise Promise Undermined
Trump Claims Modi Pledged India Would End Russian Oil Imports Amid U.S. Tariff Pressure
Surging AI Startup Valuations Fuel Bubble Concerns Among Top Investors
Australian Punter Archie Wilson Tears Up During Nebraska Press Conference, Sparking Conversation on Male Vulnerability
Australia Confirms U.S. Access to Upgraded Submarine Shipyard Under AUKUS Deal
“Firepower” Promised for Ukraine as NATO Ministers Meet — But U.S. Tomahawks Remain Undecided
Brands Confront New Dilemma as Extremists Adopt Fashion Labels
The Sydney Sweeney and Jeans Storm: “The Outcome Surpassed Our Wildest Dreams”
Erika Kirk Delivers Moving Tribute at White House as Trump Awards Charlie Presidential Medal of Freedom
British Food Influencer ‘Big John’ Detained in Australia After Visa Dispute
ScamBodia: The Chinese Fraud Empire Shielded by Cambodia’s Ruling Elite
French PM Suspends Macron’s Pension Reform Until After 2027 in Bid to Stabilize Government
Orange, Bouygues and Free Make €17 Billion Bid for Drahi’s Altice France Telecom Assets
Dutch Government Seizes Chipmaker After U.S. Presses for Removal of Chinese CEO
Bessent Accuses China of Dragging Down Global Economy Amid New Trade Curbs
U.S. Revokes Visas of Foreign Nationals Who ‘Celebrated’ Charlie Kirk’s Assassination
AI and Cybersecurity at Forefront as GITEX Global 2025 Kicks Off in Dubai
DJI Loses Appeal to Remove Pentagon’s ‘Chinese Military Company’ Label
EU Deploys New Biometric Entry/Exit System: What Non-EU Travelers Must Know
Australian Prime Minister’s Private Number Exposed Through AI Contact Scraper
×